Most cited papers from Dermatologikum Hamburg

Dermatologikum Hamburg

What are the most cited papers from Dermatologikum Hamburg?

The most cited paper from Dermatologikum Hamburg is "Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy" (Charles J. Ryan et al., 2012), with 2,827 citations. Next come "Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials" (2,004) and "Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)" (1,365).

Published TypeFieldAccessCitations

Showing 50 of 60 papers. Every paper with more than 164 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy Charles J. Ryan et al. · New England Journal of Medicine Open access	10 Dec 2012	2,827
2	Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials Richard G B Langley, Boni Elizabeth Elewski, Mark Lebwohl et al. · New England Journal of Medicine Open access	9 Jul 2014	2,004
3	Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) Kim Alexander Papp, Richard G B Langley, Mark Lebwohl et al. · The Lancet	May 2008	1,365
4	Definition of treatment goals for moderate to severe psoriasis: a European consensus Ulrich Mrowietz et al. · Archives of Dermatological Research Open access	20 Sep 2010	898
5	Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis Kenneth B. Gordon, Andrew Blauvelt, Kim Alexander Papp et al. · New England Journal of Medicine Open access	8 Jun 2016	855
6	Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials Christopher E.M. Griffiths, Kristian Reich, Mark Lebwohl et al. · The Lancet	13 Jun 2015	842
7	Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial Kristian Reich, April Wang Armstrong, Peter Anthony Foley et al. · Journal of the American Academy of Dermatology Open access	4 Jan 2017	767
8	European S3‐Guidelines on the systemic treatment of psoriasis vulgaris Delano Pathirana et al. · Journal of the European Academy of Dermatology and Venereology Open access	26 Aug 2009	705
9	Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1) Kim Alexander Papp, Kristian Reich, Craig L. Leonardi et al. · Journal of the American Academy of Dermatology Open access	16 Jun 2015	680
10	ART in Europe, 2014: results generated from European registries by ESHRE† C. De Geyter et al. · Human Reproduction Open access	18 Jun 2018	650
11	Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials Kristian Reich, Kim Alexander Papp, Andrew Blauvelt et al. · The Lancet	6 Jun 2017	565
12	Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey Mark Lebwohl, Hervé Bachelez, Jonathan Barker et al. · Journal of the American Academy of Dermatology	24 Feb 2014	517
13	Impella Support for Acute Myocardial Infarction Complicated by Cardiogenic Shock Benedikt Schrage et al. · Circulation Open access	17 Jan 2019	514
14	Epidemiology and comorbidity of psoriasis in children Matthias Augustin, Gerd Glaeske, Marc Alexander Radtke et al. · British Journal of Dermatology	18 Nov 2009	495
15	ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children Andreas Wollenberg et al. · Journal of the European Academy of Dermatology and Venereology Open access	17 Nov 2020	481
16	Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t Marjolein S. de Bruin-Weller, Diamant Thaçi, Catherine Smith et al. · British Journal of Dermatology Open access	29 Nov 2017	478
17	A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis Kim Alexander Papp, Kristian Reich, Carle F. Paul et al. · British Journal of Dermatology Open access	25 Feb 2016	470
18	Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial Michael Robert Migden et al. · The Lancet Oncology	13 May 2015	438
19	Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up Kim Alexander Papp, Christopher E.M. Griffiths, Kenneth B. Gordon et al. · British Journal of Dermatology	10 Jan 2013	415
20	Guidelines for measurement skin colour and erythema A report from the Standardization Group of the European Society of Contact Dermatitis* Ann Fullerton, Tobias W. Fischer, Anna-Maija Lahti et al. · Contact Dermatitis	Jul 1996	410
21	European S3‐Guidelines on the systemic treatment of psoriasis vulgaris – Update 2015 – Short version – EDF in cooperation with EADV and IPC Alexander Nast et al. · Journal of the European Academy of Dermatology and Venereology Open access	19 Oct 2015	400
22	ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients Andreas Wollenberg, A. P. Oranje, Mette Sondergaard Deleuran et al. · Journal of the European Academy of Dermatology and Venereology Open access	23 Mar 2016	396
23	Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis Kristian Reich, Karsten Krüger, Rotraut Mößner et al. · British Journal of Dermatology	4 Feb 2009	394
24	Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials Eric Lawrence Simpson et al. · British Journal of Dermatology	30 Jan 2020	391
25	The concept of psoriasis as a systemic inflammation: implications for disease management Kristian Reich · Journal of the European Academy of Dermatology and Venereology Open access	22 Feb 2012	361
26	Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase Marcus Maurer et al. · Journal of Allergy and Clinical Immunology Open access	19 Jun 2011	360
27	Co-morbidity and Age-related Prevalence of Psoriasis: Analysis of Health Insurance Data in Germany Matthias Augustin, Kristian Reich, Gerd Glaeske et al. · Acta Dermato Venereologica Open access	2010	337
28	Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study Andrew Blauvelt, Kristian Reich, Tsen‐Fang Tsai et al. · Journal of the American Academy of Dermatology	20 Sep 2016	312
29	Mid‐term results of Autologous Matrix‐Induced Chondrogenesis for treatment of focal cartilage defects in the knee Justus Gille, E. Schuseil, Julia Wimmer et al. · Knee Surgery Sports Traumatology Arthroscopy	Feb 2010	308
30	A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis Kenneth B. Gordon, Kristina Callis Duffin, Robert Bissonnette et al. · New England Journal of Medicine Open access	8 Jul 2015	305
31	Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis Peter C.M. van de Kerkhof, Christopher E.M. Griffiths, Kristian Reich et al. · Journal of the American Academy of Dermatology	12 May 2016	304
32	Antipsoriatic effect of fumaric acid derivatives Peter Josef Altmeyer, Ulrich Mattlies, F Pawlak et al. · Journal of the American Academy of Dermatology	Jun 1994	301
33	Evaluating Real-World Clinical Outcomes in Atrial Fibrillation Patients Receiving the WATCHMAN Left Atrial Appendage Closure Technology Lucas V.A. Boersma et al. · Circulation Arrhythmia and Electrophysiology Open access	Apr 2019	288
34	Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial Kim Alexander Papp, Diamant Thaçi, Kristian Reich et al. · British Journal of Dermatology Open access	3 Jun 2015	275
35	Disease Severity, Quality of Life and Health Care in Plaque-Type Psoriasis: A Multicenter Cross-Sectional Study in Germany Matthias Augustin, Karsten Krüger, Marc Alexander Radtke et al. · Dermatology	2008	273
36	S3 – Guidelines on the treatment of psoriasis vulgaris (English version). Update Alexander Nast et al. · JDDG Journal der Deutschen Dermatologischen Gesellschaft Open access	Mar 2012	272
37	Survey on ART and IUI: legislation, regulation, funding and registries in European countries Carlos Calhaz–Jorge, C h De Geyter, Markus S. Kupka et al. · Human Reproduction Open Open access	2020	265
38	Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study Mette Sondergaard Deleuran et al. · Journal of the American Academy of Dermatology Open access	30 Jul 2019	259
39	Treatment of the incompetent great saphenous vein by endovenous radiofrequency powered segmental thermal ablation: First clinical experience Thomas Michael Proebstle, Bernadette Vago, Jens Alm et al. · Journal of Vascular Surgery Open access	2008	259
40	Patient-Oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe Jean François Stalder et al. · Allergy Open access	18 Mar 2011	259
41	Interleukin‐17A: a unique pathway in immune‐mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis Bruce W Kirkham, Arthur Kavanaugh, Kristian Reich · Immunology Open access	2 Jul 2013	246
42	Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks Esther von Stebut, Kristian Reich, Diamant Thaçi et al. · Journal of Investigative Dermatology Open access	30 Nov 2018	227
43	Evidence that a neutrophil–keratinocyte crosstalk is an early target of IL ‐17A inhibition in psoriasis Kristian Reich et al. · Experimental Dermatology Open access	2 Apr 2015	211
44	Nail psoriasis in Germany: epidemiology and burden of disease Matthias Augustin, Kristian Reich, Christine Blome et al. · British Journal of Dermatology	28 Apr 2010	208
45	Long‐term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 2 study through 5 years of follow‐up Richard G B Langley, Mark Lebwohl, Gerald G. Krueger et al. · British Journal of Dermatology Open access	11 Oct 2014	206
46	Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1) Juliet N. Barker, Matthias Hoffmann, Gottfried Wozel et al. · British Journal of Dermatology	12 Sep 2011	204
47	The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlled trial (LIBERATE) Kristian Reich, Melinda Gooderham, L. Green et al. · Journal of the European Academy of Dermatology and Venereology Open access	21 Oct 2016	202
48	Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials Kristian Reich, A. David Burden, James Eaton et al. · British Journal of Dermatology Review	12 Sep 2011	202
49	Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials Stefan Schreiber, Jean‐Frédéric Colombel, Brian G. Feagan et al. · Annals of the Rheumatic Diseases Open access	12 Mar 2019	200
50	A 52-Week Trial Comparing Briakinumab with Methotrexate in Patients with Psoriasis Kristian Reich, Richard G B Langley, Kim Alexander Papp et al. · New England Journal of Medicine Open access	26 Oct 2011	198

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.